Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Carlton AL, Illendula A, Gao Y, Llaneza DC, Boulton A, Shah A, Rajewski RA, Landen CN, Wotton D, Bushweller JH.

Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.

2.

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.

Oo ZM, Illendula A, Grembecka J, Schmidt C, Zhou Y, Esain V, Kwan W, Frost I, North TE, Rajewski RA, Speck NA, Bushweller JH.

Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.

3.

Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131].

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2017 Nov;25:188. doi: 10.1016/j.ebiom.2017.10.029. Epub 2017 Oct 31. No abstract available.

4.

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2016 Jun;8:117-131. doi: 10.1016/j.ebiom.2016.04.032. Epub 2016 Apr 29. Erratum in: EBioMedicine. 2017 Nov;25:188.

5.

Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.

Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, Rajewski RA, Guzman ML, Castilla LH, Bushweller JH.

Science. 2015 Feb 13;347(6223):779-84. doi: 10.1126/science.aaa0314.

6.

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA.

Assay Drug Dev Technol. 2013 Oct;11(8):478-88. doi: 10.1089/adt.2012.498. Epub 2013 Oct 15.

7.

A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Kambhampati S, Rajewski RA, Tanol M, Haque I, Das A, Banerjee S, Jha S, Burns D, Borrego-Diaz E, Van Veldhuizen PJ, Banerjee SK.

Mol Cancer Ther. 2013 Mar;12(3):255-63. doi: 10.1158/1535-7163.MCT-12-0777. Epub 2013 Jan 3.

8.

Professor Valentino J. Stella: scientist, mentor, entrepreneur, family man, and giant in pharmaceutical chemistry.

Oliyai R, Brewster ME, Ozeki T, Rajewski RA, Charman W.

J Pharm Sci. 2012 Sep;101(9):2989-95. doi: 10.1002/jps.23179. Epub 2012 May 30. No abstract available.

PMID:
22648793
9.
10.

Hemodynamic profile in rabbits of fospropofol disodium injection relative to propofol emulsion following rapid bolus injection.

McIntosh MP, Iwasawa K, Rajewski RA, Fujisawa T, Goto H.

J Pharm Sci. 2012 Sep;101(9):3518-25. doi: 10.1002/jps.23162. Epub 2012 Apr 23.

PMID:
22529044
11.

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA.

BMC Cancer. 2011 Oct 31;11:468. doi: 10.1186/1471-2407-11-468.

12.

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS.

J Med Chem. 2011 Jun 9;54(11):3839-53. doi: 10.1021/jm200148p. Epub 2011 May 9.

13.

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.

14.

Mechanisms of amine accumulation in, and egress from, lysosomes.

Goldman SD, Funk RS, Rajewski RA, Krise JP.

Bioanalysis. 2009 Nov;1(8):1445-59. doi: 10.4155/bio.09.128. Review.

15.

Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice.

Urban MJ, Li C, Yu C, Lu Y, Krise JM, McIntosh MP, Rajewski RA, Blagg BS, Dobrowsky RT.

ASN Neuro. 2010 Aug 11;2(4):e00040. doi: 10.1042/AN20100015.

16.

Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys.

Kapetanovic IM, Muzzio M, Hu SC, Crowell JA, Rajewski RA, Haslam JL, Jong L, McCormick DL.

Cancer Chemother Pharmacol. 2010 May;65(6):1109-16. doi: 10.1007/s00280-009-1116-4. Epub 2009 Sep 16.

PMID:
19756605
17.

KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD.

Mol Pharmacol. 2009 Dec;76(6):1314-22. doi: 10.1124/mol.109.058545. Epub 2009 Sep 9.

18.

Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.

Roby KF, Niu F, Rajewski RA, Decedue C, Subramaniam B, Terranova PF.

Adv Exp Med Biol. 2008;622:169-81. Review. No abstract available.

PMID:
18546627
19.

Pharmacokinetics of DS-96, an alkylpolyamine lipopolysaccharide sequestrant, in rodents.

Shrestha A, Li R, Sil D, Pardeshi NN, Schwarting N, Schorno KS, Rajewski RA, Datta A, David SA.

J Pharm Sci. 2008 Dec;97(12):5376-85. doi: 10.1002/jps.21361.

PMID:
18383338
20.

Single quadrupole mass spectrometry for pre-clinical pharmacokinetic analysis: quantitation of carvedilol in dog plasma.

McIntosh MP, Carlson BJ, Schorno KS, Rajewski RA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):665-8. Epub 2007 Feb 20.

PMID:
17468057
21.

Evaluation of mean arterial blood pressure, heart rate, and sympathetic nerve activity in rabbits after administration of two formulations of etomidate.

McIntosh MP, Narita H, Kameyama Y, Rajewski RA, Goto H.

Vet Anaesth Analg. 2007 May;34(3):149-56.

PMID:
17444927
22.

Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.

Michaelis ML, Georg G, Telikepalli H, McIntosh M, Rajewski RA.

Curr Alzheimer Res. 2006 Jul;3(3):215-9. Review. Erratum in: Curr Alzheimer Res. 2009 Jun;6(3):320. Georg, G [added]; Telikepalli, H [added]; McIntosh, M [added]; Rajewski, R A [added].

PMID:
16842098
23.

Preliminary evaluation of polymer-based drug composite microparticle production by coacervate desolvation with supercritical carbon dioxide.

Yasuji T, Haslam J, Kajiyama A, McIntosh MP, Rajewski RA.

J Pharm Sci. 2006 Mar;95(3):581-8.

PMID:
16419052
24.

Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).

Okimoto K, Tokunaga Y, Ibuki R, Irie T, Uekama K, Rajewski RA, Stella VJ.

Int J Pharm. 2004 Nov 22;286(1-2):81-8.

PMID:
15501004
25.

In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation.

McIntosh MP, Schwarting N, Rajewski RA.

J Pharm Sci. 2004 Oct;93(10):2585-94.

PMID:
15349968
26.

Micronization of insulin from halogenated alcohol solution using supercritical carbon dioxide as an antisolvent.

Snavely WK, Subramaniam B, Rajewski RA, Defelippis MR.

J Pharm Sci. 2002 Sep;91(9):2026-39.

PMID:
12210049
27.
28.

A simple and efficient high-performance liquid chromatographic assay for etomidate in plasma.

McIntosh MP, Rajewski RA.

J Pharm Biomed Anal. 2001 Feb;24(4):689-94.

PMID:
11272327
30.

Stability of rifabutin in two extemporaneously compounded oral liquids.

Haslam JL, Egodage KL, Chen Y, Rajewski RA, Stella V.

Am J Health Syst Pharm. 1999 Feb 15;56(4):333-6.

PMID:
10690216
31.

Comparative effects of (SBE)7m-beta-CD and HP-beta-CD on the stability of two anti-neoplastic agents, melphalan and carmustine.

Ma DQ, Rajewski RA, Vander Velde D, Stella VJ.

J Pharm Sci. 2000 Feb;89(2):275-87.

PMID:
10688757
32.

New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD.

Ma DQ, Rajewski RA, Stella VJ.

Int J Pharm. 1999 Nov 5;189(2):227-34.

PMID:
10536251
33.

Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)(7m)-beta-CD as both a solubilizer and osmotic agent.

Okimoto K, Ohike A, Ibuki R, Aoki O, Ohnishi N, Rajewski RA, Stella VJ, Irie T, Uekama K.

J Control Release. 1999 Aug 5;60(2-3):311-9.

PMID:
10425336
34.

Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-beta-CD.

Okimoto K, Ohike A, Ibuki R, Aoki O, Ohnishi N, Irie T, Uekama K, Rajewski RA, Stella VJ.

Pharm Res. 1999 Apr;16(4):549-54.

PMID:
10227711
35.
36.

Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7m-beta-CD.

Okimoto K, Miyake M, Ohnishi N, Rajewski RA, Stella VJ, Irie T, Uekama K.

Pharm Res. 1998 Oct;15(10):1562-8.

PMID:
9794499
37.

Pharmaceutical processing with supercritical carbon dioxide.

Subramaniam B, Rajewski RA, Snavely K.

J Pharm Sci. 1997 Aug;86(8):885-90.

PMID:
9269864
38.

Cyclodextrins: their future in drug formulation and delivery.

Stella VJ, Rajewski RA.

Pharm Res. 1997 May;14(5):556-67. Review.

PMID:
9165524
39.

Isolation and characterization by NMR spectroscopy of three monosubstituted 4-sulfobutyl ether derivatives of cyclomaltoheptaose (beta-cyclodextrin).

Luna EA, Vander Velde DG, Tait RJ, Thompson DO, Rajewski RA, Stella VJ.

Carbohydr Res. 1997 Apr 21;299(3):111-8.

PMID:
9163893
40.

Fractionation and characterization of 4-sulfobutyl ether derivatives of cyclomaltoheptaose (beta-cyclodextrin).

Luna EA, Bornancini ER, Thompson DO, Rajewski RA, Stella VJ.

Carbohydr Res. 1997 Apr 21;299(3):103-10.

PMID:
9163892
41.

Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether beta-cyclodextrins with steroids.

Zia V, Rajewski RA, Bornancini ER, Luna EA, Stella VJ.

J Pharm Sci. 1997 Feb;86(2):220-4.

PMID:
9040099
42.

Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery.

Rajewski RA, Stella VJ.

J Pharm Sci. 1996 Nov;85(11):1142-69. Review.

PMID:
8923319
43.

Evaluation of the utility of capillary electrophoresis for the analysis of sulfobutyl ether beta-cyclodextrin mixtures.

Luna EA, Bornancini ER, Tait RJ, Thompson DO, Stobaugh JF, Rajewski RA, Stella VJ.

J Pharm Biomed Anal. 1996 Oct;15(1):63-71.

PMID:
8895077
44.

The interaction of charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta-CD) beta-cyclodextrins.

Okimoto K, Rajewski RA, Uekama K, Jona JA, Stella VJ.

Pharm Res. 1996 Feb;13(2):256-64.

PMID:
8932446
45.

Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives.

Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson DO.

J Pharm Sci. 1995 Aug;84(8):927-32. Erratum in: J Pharm Sci 1995 Dec;84(12):1492.

PMID:
7500275
46.

Stereo-specific analysis of a novel protein kinase C inhibitor.

Rajewski RA, Kosednar DG, Matches TA, Wong OS, Burchett K, Thakker K.

J Pharm Biomed Anal. 1995 Mar;13(3):247-53.

PMID:
7619884
47.

Characterization of sulphoalkyl ether derivatives of beta-cyclodextrin by capillary electrophoresis with indirect UV detection.

Tait RJ, Skanchy DJ, Thompson DP, Chetwyn NC, Dunshee DA, Rajewski RA, Stella VJ, Stobaugh JF.

J Pharm Biomed Anal. 1992 Sep;10(9):615-22.

PMID:
1286127

Supplemental Content

Loading ...
Support Center